<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02336958</url>
  </required_header>
  <id_info>
    <org_study_id>A 2013-0075</org_study_id>
    <nct_id>NCT02336958</nct_id>
  </id_info>
  <brief_title>Ultrasound Guided Intermediate Cervical Plexus Block and Additional Perivascular Local Anesthetic Infiltration</brief_title>
  <official_title>Ultrasound Guided Intermediate Cervical Plexus Block -Randomized Evaluation Concerning the Significance of Additional Perivascular Local Anesthetic Infiltration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helios Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helios Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For ultrasound guided intermediate cervical plexus block this randomized comparison is
      testing the hypothesis, that an additional perivascular infiltration is associated with
      increased block quality.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The innervation of the neck is complex and involves the cervical and the brachial plexus as
      well as cranial nerves. So is the wall of the carotid arteries innervated by vagal and
      glossopharyngeal nerve as well as the sympathetic trunk. When carotid surgery was performed
      under regional anesthesia, so additional infiltration of local anesthetic by the surgeon was
      common, particularly during preparation of the carotid arteries.

      Introduction of ultrasound guidance made it possible to guide the needle directly to the
      vascular wall. But this procedure is considered very demanding, because of guiding the needle
      in an anatomical region with artifacts (because of calcification), sudden movements (e.g.
      because of swallowing) and compromised coagulation (antithrombotic medication). On the other
      side there are no clinical data proving the benefit of an additional perivascular
      infiltration with local anesthetic. Therefore, this investigation is testing the hypothesis,
      that an additional perivascular infiltration is associated with increased block quality.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Required Supplementation of Local Anesthetic by Surgeon</measure>
    <time_frame>during the intraoperative period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount (ml) of Local Anesthetic Supplemented by Surgeon</measure>
    <time_frame>during the intraoperative period</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Carotid Stenosis</condition>
  <arm_group>
    <arm_group_label>ropivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ultrasound guided intermediate cervical plexus block: 20ml ropivacaine 0.75%. Ultrasound guided perivascular/pericarotidal infiltration: 5ml ropivacaine 0.75%.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Ultrasound guided intermediate cervical plexus block: 20ml ropivacaine 0.75%. Ultrasound guided perivascular/pericarotidal infiltration: 5ml saline 0.9%.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intermediate cervical plexus block ropivacaine</intervention_name>
    <description>20ml ultrasound guided intermediate cervical plexus block.</description>
    <arm_group_label>ropivacaine</arm_group_label>
    <arm_group_label>saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pericarotidal infiltration (active comparator) ropivacaine</intervention_name>
    <description>5ml ropivacaine 0.75% (active comparator): pericarotidal infiltration.</description>
    <arm_group_label>ropivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>jugular infiltration prilocaine</intervention_name>
    <description>5ml prilocaine 1% jugular infiltration for wound drainage.</description>
    <arm_group_label>ropivacaine</arm_group_label>
    <arm_group_label>saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pericarotidal infiltration (placebo comparator) saline</intervention_name>
    <description>5ml saline 0.9% (placebo comparator): pericarotidal infiltration.</description>
    <arm_group_label>saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  carotid surgery (symptomatic and asymptomatic carotid stenosis)

          -  adult patients (18 years or older)

          -  ASA-risk-groups I-IV

          -  informed consent

        Exclusion Criteria:

          -  drug allergy: local anesthetics

          -  pregnancy, lactation period

          -  participation in other studies

          -  addiction to drugs or alcohol

          -  non-cooperative patients

          -  no approval to regional anesthesia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Seidel, Dr.med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helios Kliniken Schwerin, Klinik für Anästhesiologie und Intensivtherapie, Wismarsche Strasse 393-7, 19049 Schwerin, Germany</affiliation>
  </overall_official>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2015</study_first_submitted>
  <study_first_submitted_qc>January 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2015</study_first_posted>
  <results_first_submitted>March 12, 2015</results_first_submitted>
  <results_first_submitted_qc>March 12, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 23, 2015</results_first_posted>
  <last_update_submitted>March 12, 2015</last_update_submitted>
  <last_update_submitted_qc>March 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helios Research Center</investigator_affiliation>
    <investigator_full_name>Dr.med.Ronald Seidel</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>cervical plexus</keyword>
  <keyword>regional anesthesia</keyword>
  <keyword>ultrasound</keyword>
  <keyword>carotid surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carotid Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>Prilocaine</mesh_term>
    <mesh_term>Anesthetics, Local</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ropivacaine</title>
          <description>Ultrasound guided intermediate cervical plexus block: 20ml ropivacaine 0.75%. Ultrasound guided perivascular/pericarotidal infiltration: 5ml ropivacaine 0.75%.
intermediate cervical plexus block ropivacaine: 20ml ultrasound guided intermediate cervical plexus block.
pericarotidal infiltration (active comparator) ropivacaine: 5ml ropivacaine 0.75% (active comparator): pericarotidal infiltration.
jugular infiltration prilocaine: 5ml prilocaine 1% jugular infiltration for wound drainage.</description>
        </group>
        <group group_id="P2">
          <title>Saline</title>
          <description>Ultrasound guided intermediate cervical plexus block: 20ml ropivacaine 0.75%. Ultrasound guided perivascular/pericarotidal infiltration: 5ml saline 0.9%.
intermediate cervical plexus block ropivacaine: 20ml ultrasound guided intermediate cervical plexus block.
jugular infiltration prilocaine: 5ml prilocaine 1% jugular infiltration for wound drainage.
pericarotidal infiltration (placebo comparator) saline: 5ml saline 0.9% (placebo comparator): pericarotidal infiltration.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ropivacaine</title>
          <description>Ultrasound guided intermediate cervical plexus block: 20ml ropivacaine 0.75%. Ultrasound guided perivascular/pericarotidal infiltration: 5ml ropivacaine 0.75%.
intermediate cervical plexus block ropivacaine: 20ml ultrasound guided intermediate cervical plexus block.
pericarotidal infiltration (active comparator) ropivacaine: 5ml ropivacaine 0.75% (active comparator): pericarotidal infiltration.
jugular infiltration prilocaine: 5ml prilocaine 1% jugular infiltration for wound drainage.</description>
        </group>
        <group group_id="B2">
          <title>Saline</title>
          <description>Ultrasound guided intermediate cervical plexus block: 20ml ropivacaine 0.75%. Ultrasound guided perivascular/pericarotidal infiltration: 5ml saline 0.9%.
intermediate cervical plexus block ropivacaine: 20ml ultrasound guided intermediate cervical plexus block.
jugular infiltration prilocaine: 5ml prilocaine 1% jugular infiltration for wound drainage.
pericarotidal infiltration (placebo comparator) saline: 5ml saline 0.9% (placebo comparator): pericarotidal infiltration.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.9" spread="9.0"/>
                    <measurement group_id="B2" value="72.2" spread="7.7"/>
                    <measurement group_id="B3" value="71.5" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Required Supplementation of Local Anesthetic by Surgeon</title>
        <time_frame>during the intraoperative period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ropivacaine</title>
            <description>Ultrasound guided intermediate cervical plexus block: 20ml ropivacaine 0.75%. Ultrasound guided perivascular/pericarotidal infiltration: 5ml ropivacaine 0.75%.
intermediate cervical plexus block ropivacaine: 20ml ultrasound guided intermediate cervical plexus block.
pericarotidal infiltration (active comparator) ropivacaine: 5ml ropivacaine 0.75% (active comparator): pericarotidal infiltration.
jugular infiltration prilocaine: 5ml prilocaine 1% jugular infiltration for wound drainage.</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Ultrasound guided intermediate cervical plexus block: 20ml ropivacaine 0.75%. Ultrasound guided perivascular/pericarotidal infiltration: 5ml saline 0.9%.
intermediate cervical plexus block ropivacaine: 20ml ultrasound guided intermediate cervical plexus block.
jugular infiltration prilocaine: 5ml prilocaine 1% jugular infiltration for wound drainage.
pericarotidal infiltration (placebo comparator) saline: 5ml saline 0.9% (placebo comparator): pericarotidal infiltration.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Required Supplementation of Local Anesthetic by Surgeon</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Amount (ml) of Local Anesthetic Supplemented by Surgeon</title>
        <time_frame>during the intraoperative period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ropivacaine</title>
            <description>Ultrasound guided intermediate cervical plexus block: 20ml ropivacaine 0.75%. Ultrasound guided perivascular/pericarotidal infiltration: 5ml ropivacaine 0.75%.
intermediate cervical plexus block ropivacaine: 20ml ultrasound guided intermediate cervical plexus block.
pericarotidal infiltration (active comparator) ropivacaine: 5ml ropivacaine 0.75% (active comparator): pericarotidal infiltration.
jugular infiltration prilocaine: 5ml prilocaine 1% jugular infiltration for wound drainage.</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Ultrasound guided intermediate cervical plexus block: 20ml ropivacaine 0.75%. Ultrasound guided perivascular/pericarotidal infiltration: 5ml saline 0.9%.
intermediate cervical plexus block ropivacaine: 20ml ultrasound guided intermediate cervical plexus block.
jugular infiltration prilocaine: 5ml prilocaine 1% jugular infiltration for wound drainage.
pericarotidal infiltration (placebo comparator) saline: 5ml saline 0.9% (placebo comparator): pericarotidal infiltration.</description>
          </group>
        </group_list>
        <measure>
          <title>Amount (ml) of Local Anesthetic Supplemented by Surgeon</title>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" lower_limit="2.2" upper_limit="7.6"/>
                    <measurement group_id="O2" value="3.7" lower_limit="1.7" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.459</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>during the intraoperative period</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ropivacaine</title>
          <description>Ultrasound guided intermediate cervical plexus block: 20ml ropivacaine 0.75%. Ultrasound guided perivascular/pericarotidal infiltration: 5ml ropivacaine 0.75%.
intermediate cervical plexus block ropivacaine: 20ml ultrasound guided intermediate cervical plexus block.
pericarotidal infiltration (active comparator) ropivacaine: 5ml ropivacaine 0.75% (active comparator): pericarotidal infiltration.
jugular infiltration prilocaine: 5ml prilocaine 1% jugular infiltration for wound drainage.</description>
        </group>
        <group group_id="E2">
          <title>Saline</title>
          <description>Ultrasound guided intermediate cervical plexus block: 20ml ropivacaine 0.75%. Ultrasound guided perivascular/pericarotidal infiltration: 5ml saline 0.9%.
intermediate cervical plexus block ropivacaine: 20ml ultrasound guided intermediate cervical plexus block.
jugular infiltration prilocaine: 5ml prilocaine 1% jugular infiltration for wound drainage.
pericarotidal infiltration (placebo comparator) saline: 5ml saline 0.9% (placebo comparator): pericarotidal infiltration.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>definitive stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>temporarily hoarseness</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="20"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>temporarily dysphagia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="20"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Horner syndrome</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>temporarily paresis of the hypoglossal nerve</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. med. Ronald Seidel</name_or_title>
      <organization>Helios Kliniken Schwerin</organization>
      <phone>0049 (0)385 5204251</phone>
      <email>ronald.seidel@helios-kliniken.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

